ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity
John A. Moral(Parker Institute for Cancer Immunotherapy), Joanne Leung(Parker Institute for Cancer Immunotherapy), Luis A. Rojas(Memorial Sloan Kettering Cancer Center), Jennifer Jin Ruan(Parker Institute for Cancer Immunotherapy), Julia N. Zhao(Parker Institute for Cancer Immunotherapy), Zachary Sethna(Parker Institute for Cancer Immunotherapy), Anita Ramnarain(Parker Institute for Cancer Immunotherapy), Billel Gasmi(Swim Across America), Murali Gururajan(Bristol-Myers Squibb (United States)), David Redmond(Cornell University), Gökçe Aşkan(Memorial Sloan Kettering Cancer Center), Umesh Bhanot(Memorial Sloan Kettering Cancer Center), Ela Elyada(Cold Spring Harbor Laboratory), Youngkyu Park(Lustgarten Foundation), David A. Tuveson(Lustgarten Foundation), Mithat Gönen(Memorial Sloan Kettering Cancer Center), Steven D. Leach(Dartmouth College), Jedd D. Wolchok(Memorial Sloan Kettering Cancer Center), Ronald P. DeMatteo(University of Pennsylvania), Taha Merghoub(Memorial Sloan Kettering Cancer Center), Vinod P. Balachandran(Memorial Sloan Kettering Cancer Center)
Cited by 339Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis